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A B ST R AC T  
 
Aimː To evaluate data from our hospital system before and after the implementation of the Bethesda 
System for Reporting Thyroid Cytology (TBSRTC) and comparison of our data with the previously 
published studies. 
Methods: Seven hundred seventy-one patients with thyroid nodules who underwent fine needle 
aspiration biopsy (FNAB) and surgery at our institution were analyzed retrospectively. FNAB 
results were divided into two parts in terms of the period they related to: pre-TBSRTC (between 2005 
and 2010) and TBSRTC (between 2011 and 2013). 
Results: 341 FNAB were applied in the period of TBSRTC. Of the 341 FNAB, 53(16%) were non 
diagnostic, 82(24%) were benign, 62(18%) were atypia of undetermined significance or follicular 
lesion of undetermined significance (AUS/FLUS), 28(8%) were follicular neoplasms and/or 
suspicion of follicular neoplasms (FN/SFN), 95(28%) were suspicion for malignancy (SuspM), and 
21(6%) were malignant. Rates of malignancy reported on follow-up histopathological examination 
were non diagnostic in 11%, benign in 4.9%, AUS/FLUS in 23%, FN/SFN in 32%, SuspM in 44%, 
and malignant in 95.3%. 
Conclusions: In this study, the distribution of cases in TBSRTC categories and malignancy rates, 
differed from, recommended by TBSRTC and some studies. Implementation of TBSRTC did 
significantly affect our institution’s reporting rates. 
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Introduction 
The rate of thyroid nodules which can be 
palpated in adult is between 3-7%. But in 
recent years, with more frequent use of 
imaging methods, asymptomatic thyroid 
nodules can be detected [1]. Most of the 
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thyroid nodule is benign. American Thyroid 
Association Guideline has reported in 2009 
that thyroid cancer could occur in thyroid 
nodules at the ratios between 5-15% [2]. The 
basic approach in the evaluation of thyroid 
nodules is to identify the nodules as benign-
malignant and to evaluate treatment method to 
be applied. Fine needle aspiration biopsy 
(FNAB) is assumed to be the most appropriate 
and least invasive method used to identify the 
nodules as benign or malignant [3,4].  
Prior to The Bethesda System for Reporting 
Thyroid Cytopathology (TBSRTC), thyroid 
FNAB terminology varied significantly 
between the centers and some confusion was 
emerged, which caused trouble in sharing of 
clinical aspects between various institutes [5]. 
The development of a common terminology 
was decided in Bethesda Conference in 2007, 
which was arranged by National Cancer 
Institute (NCI). Firstly, in NCI conference held 
in 1988; the Bethesda System was examplified, 
which was developed for reporting of cervical 
cytology diagnosis. FNAB results has been 
aggregated in six different diagnostic 
categories in TBSRTC, and possible risks of 
malignancy and general approach have been 
determined [5,6]. 
In this study, FNAB results and malignancy 
rates for each FNAB category, false-negative 
(FN) rates were calculated in the periods of 
TBSRTC and pre-TBSRTC implementation in 
out clinic. We aimed to compare our data in the 
periods of TBSRTC and pre-TBSRTC 
implementation with the previously published 
data in the world. 
 
Methods 
In this study, 771 patients were included 
retrospectively, whom thyroidectomy was 
performed including FNAB, in Ondokuz 
Mayıs University, Faculty of Medicine, 
department of General Surgery, between the 
dates January 2005 and December 2013. The 
results of FNAB, applied in the centers other 
than our clinic and the head and neck 
malignancies except thyroid cancer, to which 
thyroidectomy has been performed, were not 
included to this study. 
The nodules, evaluated by using clinical 
ultrasound (USG) and FNAB, were defined as 
index (target) nodules. 
In all  Patients’ FNAB was performed using a 
22 gauge needle  with 10 or 20 mL syringe in 
accompany of USG, without  local anesthesia 
following disinfection of the  skin. After 
smears were fixed locating into the bottles with 
95% ethyl alcohol, they were evaluated by 
using Papanicolau method. The examples, 
each group of which includes at least 10 cells 
and containing follicular cells at least within 6 
groups, were considered suitable for 
evaluation [5,6]. 
Fine needle aspiration (FNA) cytology 
results were divided into two parts in terms of 
the period of TBSRTC (between 2011 and 
2013) and the period of pre-TBSRTC (between 
2005 and 2010). The thyroid nodules in the 
period of pre-TBSRTC were classified into 
five groups: non-diagnostic (ND), benign, 
follicular neoplasms and/or suspicion of 
follicular neoplasms (FN/SFN), suspicion for 
malignancy (SuspM), and malignant (7). 
The thyroid nodules in the period of TBSRTC 
were classified into six groups as ND, benign, 
atypia of undetermined significance or 
follicular lesion of undetermined significance 
(AUS/FLUS), FN/SFN, SuspM and malignant 
[5,6]. 
All patients who had thyroid nodules at least10 
mm on thyroid USG, underwent FNAB. In 
patients with thyroid nodules smaller than 10 
mm on USG, those with USG findings 
suspicious for malignancy, underwent FNAB 
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as well, and they underwent surgery if they had 
FNA cytology findings of malignant, SuspM, 
ND, or FN/SFN. Patients with thyroid nodules 
10 mm and <30 mm on USG underwent 
surgery if they had any one of the clinical or 
ultrasonographic features suggesting 
malignancy, such as palpable cervical lymph 
nodes, microcalcification inside the nodule, 
hypoechogenicity, or solid structure, or if they 
had FNA cytology findings of malignant, 
SuspM, ND, or FN/SFN. Patients with nodules 
30 mm on USG, underwent surgery regardless 
of FNA cytology finding, because FN rate of 
FNA cytology has been suggested to be high in 
patients with nodules 3 cm [8]. 
Thyroidectomy was performed on the patients 
whose first FNAB result is AUS/FLUS and 
also if the second recurrence of FNAB was 
reported as AUS/FLUS, FN/SFN, SuspM or 
malignant. If second FNAB reported as 
benign, observation or thyroidectomy 
indication was implemented by taking into 
account clinical, suspicious features in USG, 
and the patient's preference. 
All patients with non-diagnostic FNA cytology 
findings underwent a repeat FNA, and when a 
repeat FNA cytology was diagnostic after a 
non-diagnostic one, the second was used for 
the final clinical decision.  
If a patient had multiple FNA samples in one 
procedure diagnosis with higher malignant 
potential was used for calculating malignancy 
follow-up rates (for example if a single FNA 
had a diagnosis of "benign" and "suspicious for 
malignancy" on two separate passes, the case 
was included in the calculation for the SuspM 
follow-up rate and not for the benign group). 
The reports prepared using pathology results 
on thyroid follicular cancer, papillary thyroid 
cancer, medullary cancer, anaplastic cancer, 
lymphoma cases, malignant; nodular colloidal 
goitre, hyperplasia, adenomas, hurtle cells 
adenomas,  thyroiditis (Hashimoto thyroiditis, 
De Quervain's thyroiditis, Lymphocytic 
thyroiditis, etc.), cystic nodular goitre were 
assumed indicating benign. All patients’ 
operation pathology results and FNA 
cytological results were compared. We could 
calculate the malignancy risk for each category 
and compared it with that in other studies. 
Incidental papillary carcinomas (<1 cm) on 
resection were not considered malignant, 
except when prior cytological interpretation 
was SuspM or malignant. 
The values of FNAB, such as,  sensitivity, 
specificity, positive predictive value (PPV), 
negative predictive value (NPV), accuracy, 
FN, false positive (FP) values were calculated 
for all patients for the period of TBSRTC and 
pre-TBSRTC separately. 
A true-positive (TP) result was defined as FNA 
diagnostic findings of malignant, SuspM, 
FN/SFN coupled with malignant histology; a 
true-negative (TN) result was defined as a 
benign FNAB that was diagnosed as benign on 
histology. False-positive (FP) result was a 
FNAB result of malignant, SuspM, FN/SFN 
that had benign histology, and FN result was a 
benign FNAB with malignant histology (9). In 
the period of TBSRTC, sensitivity, specificity, 
PPV, NPV, accuracy was calculated using a 
second method. In the second method, the 
category of AUS/FLUS was included as FP in 
the calculation. 
The following formulas were used to calculate 
the sensitivity, specificity, PPV, NPV, 
accuracy values; 
Sensitivity of FNAB was defined as TP results 
divided by TP plus FN results, and specificity 
was defined as TN results divided by TN plus 
FP results. PPV was calculated as TP/ (TP + 
FP). NPV was TN/ (TN + FN). Diagnostic 
accuracy was estimated as (TP + TN)/ (TP + 
FP + TN + FN). Sensitivity, specificity, PPV, 
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NPV, and accuracy were calculated among 
patients with FNAB results. 
 
Statistical analysis 
The software of SPSS (Statistical Package for 
Social Sciences) for Windows 20.0 was used 
for statistical analysis required to evaluate the 
study findings. In the comparison of the 
qualitative data, Chi-square and Fisher's exact 
tests were used. In the present study, the p 
values less than 0.05 was considered 
significant. 
 
Results  
In our hospital between the dates January 2005 
and December 2010, 430 FNA were applied in 
the period of pre-TBSRTC, and 5 diagnostic 
category was used cytologically. The 
diagnostic category rates for the period of pre-
TBSRTC were determined as follows: ND 
64(15%), benign 187(43%), FN/SFN 13(3%), 
SuspM 151(35%) and malignant 15(4%) 
(Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Between the dates January 2011 and December 
2013, during which TBSRTC was used, it was 
seen that, 341 FNA were applied in our 
hospital, and the results of FNAB were divided 
into 6 diagnostic categories in accordance with 
TBSRTC. FNAB diagnostic category ratios for 
the period of TBSRTC were determined as 
follows: ND 53(16%), benign 82(24%), 
AUS/FLUS 62(18%), FN/SFN 28(8%), 
SuspM 95(28%) and malignant 21(6%) 
(Table1). 
It was seen that a total of 771 FNA were 
applied for the period of TBSRTC and pre-
TBSRTC in our hospital. FNAB diagnostic 
category ratios for the pre-TBSRTC and for the 
period of TBSRTC were determined as 
follows: ND 117(15%), benign 269(35%), 
AUS/FLUS 62(8%), FN/SFN 41(5%), SuspM 
246(32%) and malignant 36(5%) (Table1). 
When we review the FNAB category results 
for the pre-TBSRTC period and postoperative  
histopathology results, it was seen that 
histopathology    results   for  the categories of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        Alper et al.  Exp Biomed Res 2019; 2(3):121-131 
   
 
125 
 
ND, benign, FN/SFN, SuspM, malign FNAB 
were determined as malignant in the ratios 6%, 
3.2%, 15%, 29%, 100% (Table 2). The FN 
ratio was 3.2% for the period of pre-TBSRTC. 
FNAB results for the pre-TBSRTC were seen 
as follows: sensitivity 91%, specificity 60%, 
PPV 34%, NPV 97%, accuracy 66% (Table 3). 
FNAB diagnostic category rates for the period 
of TBSRTC and postoperative histopathology 
results were seen in Table 2; the 
histopathology results of ND, benign, 
AUS/FLUS, FN/SFN and SuspM, malignant 
FNAB results were determined as malignant in 
the ratios as follows: 11%, 4.9%, 23%, 32%, 
44% and 95.3%. The FN ratio for the period of 
TBSRTC was 4.9%. FNAB results for the 
period of TBSRTC; the following values were 
seen in Table 3 that sensitivity 95%, specificity 
52%, PPV 49%,   NPV   95%,   accuracy  66%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The sensitivity, specificity, PPV, NPV and 
accuracy were calculated using a second 
method for the period of TBSRTC. In the 
second method, AUS/FLUS category was 
included as FP in the calculation. In the second 
calculation, the values were determined as 
follows: sensitivity (95%), specificity (39%), 
PPV (41%), NPV (95%), and accuracy (57%) 
as seen sensitivity and NPV kept their previous 
ratios. FNAB diagnostic category ratios 
including all FNABs for the period of pre-
TBSRTC and TBSRTC were determined as 
follows as indicated in Table 3: sensitivity 
93%, specificity 57.5%, PPV 41%, NPV 96%, 
accuracy 66%.  
Our cytology and histopathology results for the 
period of TBSRTC and              cytology and 
histopathology results related to the studies at 
literature were indicated in Table 4 and Table 
5 (10-17). 
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Discussion 
Thyroid FNAB is a very valuable method in 
evaluation of thyroid nodules.  FNAB reduces 
unnecessary surgery ratio of the patients with 
benign nodule. The ratio of malignancy of 
thyroid nodules that was removed 
surgically has exceeded the 50% after routine 
use of the thyroid FNAB [18].  
When thyroid FNAB is evaluated, it is 
important to benefit from cytopathology 
report. For the result of FNAB being useful in 
respect        of       clinical    management,   the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
terminology used must be short, concise, and 
clear. Previously, thyroid FNAB terminology 
used to vary from one laboratory to another. 
This situation used to cause confusion and 
prevent data sharing among different 
institutions. Since 2007, these problems have 
been attempted to eliminate through TBSRTC. 
Our study is a comprehensive representation 
about thyroid FNAB and the associated 
malignancy rates performed by our surgical 
center    which   is  a tertiary  referral center in  
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Turkey. Our data was compared with the 
findings of 8 studies that was previously 
reported and the data recommended for 
TBSRTC.  While some of our data are 
compatible with the literature, some of them 
were different from it, which we tried to 
explain below. 
All FNAB results we obtained were 
respectively as follows: ND 15%, benign 35%, 
AUS/FLUS 8%, FN/SFN 5%, SuspM 32% and 
malignant 5%. In spite of applying all FNABs 
accompanying with USG, non-diagnostic 
FNAB results aren’t lower. 
It was seen in Table 1 that benign rate reduced 
in the period of TBSRTC comparing to the 
period of pre-TBSRTC (24% versus 43%), 
FN/SFN rate increased (8% versus 3%), 
SuspM ratio decreased (28% versus 35%) the 
other categories didn’t change so much. When 
these results examined, it must be considered 
that some FNAB which had to be classified in 
the category of benign, might be classified as 
AUS/FLUS, some FNAB which had to be 
classified in the category of SuspM, might be 
classified as FN/SFN. 
When FNAB diagnostic category results are 
compared with our postoperative 
histopathology results, it is seen that our 
histopathology malignancy results in all 
categories in the period of TBSRTC is higher 
than the ones in the period of pre-TBSRTC 
(Table 2). This indicates that malignancy rate 
is increased in the post period of TBSRTC. 
This increase in the rate of malignancy results 
in very important consequences in patient care 
and surgical decision making. 
In this study, for all FNABs applied in our 
clinic, the following results have been 
obtained:  sensitivity 93%, specificity 57.5%, 
PPV 41%, NPV 96% and accuracy 66% (Table 
3). In the period of TBSRTC, while sensitivity 
(95% versus 91%), and PPV (49% versus 
34%) increased, specificity (52% versus 60%) 
and NPV (95% versus 97%) decreased. 
Accuracy (66%) didn’t change. In the second 
calculation where AUS/FLUS was included in 
the study as FP, when compared to the period 
of pre-TBSRTC, it was seen that specificity 
(39% versus 60%) and accuracy (57% versus 
66%) were decreased. This situation indicates 
that inclusion of AUS/FLUS category in the 
calculation, caused FP to be increased. 
Ozluk et al., Yang et al., Wang et al., 
Bongiovanni et al., Park et al. have reported the 
sensitivity for the period of TBSRTC as 
follows: respectively; 85%, 94%, 95%, 97%, 
79.8%. In the same studies, specificity was 
reported respectively as 94%, 98.5%, 47%, 
50.7%, 99.3%; PPV was reported respectively 
as 89%, NA (not available in published study), 
52%, 55.9%, 99.3%; NPV was reported 
respectively as 92%, NA, 94%, 96.3%, 79.1%. 
Ozluk et al. reported accuracy as 90%, 
Bongiovanni et al. reported as 68.8%, but 
accuracy hasn’t been reported in other studies 
[16,19-22]. While in our study, for the period 
of TBSRTC, sensitivity (95%) and NPV (95%) 
rates were determined to be similar to the 
above studies, specificity (52%), PPV (49%) 
and accuracy (66%) rates were determined 
lower than the ones reported in above studies. 
FNAB separates successfully benign thyroid 
nodules from malignant nodules. In our study, 
the reason why the specificity, PPV and 
accuracy yielded lower values was that FP was 
high in our FNAB results. This situation can 
cause unnecessary surgery to be performed to 
the patients with nodules. The reason why 
sensitivity and NPV was high, associated with 
that FN was low in our FNAB results. Since 
FN value is low, we may not have to operate 
the patients whose FNAB result is benign if 
clinically there is not suspicious features    and 
USG findings. If we have clinical doubt, we 
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prefer using lobectomy and isthmectomy 
together instead of total thyroidectomy. Our 
study indicates that FNAB is an effective 
entity to determine the patients who are 
candidate of surgery due to the risk of 
thyroid malignancy. 
We compared FNAB results for the period of 
TBSRTC with the data of Mondal et al., Wu et 
al., Harvey et al., Marchevsky et al., Broome et 
al., Nayar and Ivanoviç, Ozluk et al., and Jo et 
al. as seen in Table 4 [10-17]. It was found out 
that our ND (16%), FN/SFN (8%) and 
malignant (6%) rates for the period of 
TBSRTC were similar with the values reported 
in other studies. Our FNAB benign (24%) rate 
for the period of TBSRTC is lower than the 
ones reported by Cibas and Ali [5] (60-70%) 
and the ones (range between 34-89%) 
indicated in Table 4, reported in other studies. 
Our AUS/FLUS results, in all FNAB and in the 
period of TBSRTC (respectively 8%, 18%) are 
higher than the recommended rate (3-6%) for 
the period of TBSRTC [5]. However, our 
AUS/FLUS rate, as shown in Table 4, was not 
higher than the rates (range from 1% to 29%), 
reported in other studies. Also our SuspM 
(28%) rate for the period of TBSRTC is higher 
the ones reported in other studies (range from 
1% to 10%). The results in Table 4 other than 
Broome et al. [14] and Ozluk et al. [16] include 
all nodules with FNAB regardless operation. 
Our results, as reported by Broome et al. and 
Ozluk et al., are data only belonged to nodules 
operated. The patients whom FNAB has been 
applied but not undergone surgery performed, 
were not included in our study. This is why our 
AUS/FLUS and SuspM results are higher than 
the ones recommended for TBSRTC period, 
and are lower than our benign results [5]. In the 
data included in the pathology department of 
our hospital, AUS/FLUS rate in all thyroid 
FNAB is about 11%. This suggests that 
AUS/FLUS diagnosis was higher than it 
supposed to be. 
Due to the fact that our hospital is a third step 
institution, the patients are selected ones, 
which may be the one of the reasons why 
benign FNAB results is low in the period of 
TBSRTC. 
In Table 5, we compared the cancer results in 
respect of histopathology in the period of 
TBSRTC with the malignancy risk rates that 
Cibas and Ali reported for the period of 
TBSRTC, and data related to various studies in 
literature [5,10-17]. In our study, the rate of the 
patients with benign outcome of FNAB and 
malignant (false negative) as a result 
of histopathology in the period of TBSRTC is 
4.9%. According to the data that Wu et al., 
Marchevsky et al., Broome et al. and Ozluk et 
al. [13,14,16], FN rate was 9.5%, 32.2%, 9%, 
10%, respectively. These results are higher 
than FN rate (0-3%) that reported by Cibas and 
Ali for the period of TBSRTC. Accordingly, 
our FN rate was under 5% and within 
acceptable limits.  
While the result of FNAB is AUS/FLUS,   
malignant histopathology ratio is 23% in our 
study, it changes in other actual studies 
between 6-37.9%. Cibas and Ali reported risk 
of malignancy for AUS/FLUS category 
between 5-15% for the period of TBSRTC 
[5,6,10-17], (Table 5). At first sight, even it 
comes into mind that malignancy rate is high 
because of that the results of our, Broome et 
al., and Ozluk et al. [14,16] (respectively 23%, 
20%, 36%) include only the data of the patients 
operated, except for Nayar and Ivanoviç 
(reported rate of malignancy as 6% in the 
category of AUS/FLUS), rate of malignancy in 
category of AUS/FLUS was reported higher 
than  the risk of malignancy that Cibas and Ali 
had reported for the period of TBSRTC in all 
other studies [5,6]. All of these results indicate 
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that specific clinical data is very important in 
treatment planning of the patients. 
Cibas and Ali reported [5,6] the malignancy 
rate of the patients who became SuspM as a 
result of FNAB as between 60-75% (5). While 
this rate was reported as between 52-100% in 
other studies, it was 44% in our study. Since 
our SuspM rate (28%) in FNAB is higher than 
the other (range between 1 and 10%) reported 
in other studies, and the rates of patients, 
became SuspM as a result of FNAB, and 
became malignant as a result of 
histopathology, is lower than the ones that 
Cibas and Ali reported [5,6] and also the ones 
reported in other studies, it brings into mind 
that some benign FNAB results was defined as 
SuspM. Also since the rate of the patients who 
became AUS/FLUS as a result of FNAB, and 
became  malignant as a result of 
histopathology (23%) is higher than the 
malignant rate that Cibas and Ali reported           
(5-15%), it brings into mind that some FNAB 
which supposed to be SuspM, would have been 
defined as AUS/FLUS [5,6]. 
The experience of pathologist will be increased 
through using of TBSRTC. Through increase 
of the experience and knowledge of 
pathologist about TBSRTC, our data can reach 
to the values that Cibas and Ali suggested 
[5,6]. As a result, FNAB is a method with high 
specificity and sensitivity for assessment of 
thyroid nodular disease. However, the 
performing way of FNAB and the experiences 
of pathologist and clinicians, affect the result 
directly. In cytological examination, corporate 
or even individual differences can exist. 
Reduction error rate can be possible with the 
development of a common language between 
clinician, radiologist and pathologist. The 
success of cytological results will be increased 
with knowledge, experience and development 
of the technical equipment. TBSRTC was 
developed for the purpose of creating a 
standard terminology and useful, however, our 
clinics haven’t enough information and 
experience about TBSRTC. Through the 
studies like ours, every clinic will increase its 
own experience by comparing its own FNAB 
data with histopathology reports and data in the 
literature thus reaching more reliable and 
precise results. 
 
Conclusions 
Although FNAB is the most cost effective and 
least invasive method in the evaluation of 
thyroid nodules in terms of malignancy, the 
data that we obtained in our study indicates 
that FNAB is very important in surgical 
indications but not sufficient alone. Even if a 
lower rate, in case FNAB results in FN may 
cause misdiagnose of cancer. The reduction of 
error rate may be possible with development of 
a common language between clinician, 
pathologist, and radiologist. The success 
of cytological results is related with 
development of standard terminology in terms 
of knowledge, experience, technical 
equipment and pathology. 
TBSRTC was developed for the purpose of 
creating a standard terminology and are known 
to be useful. The experience of the related 
disciplines of our hospital about TBSRTC, will 
be increased steadily through analysis of the 
results of this study. In our opinion, a surgeon 
should use their own institution of data in 
addition to FNAB data of other institutions 
while giving treatment recommendations and 
consulting for patients. 
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